-

Global Cord Blood Corporation (CO) Investor Notice: Robbins LLP Reminds Stockholders of the Global Cord Blood Corporation Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Global Cord Blood Corporation (NYSE: CO) securities between June 4, 2019 and May 3, 2022. Global Cord Blood provides umbilical cord blood storage and ancillary services in the in the Beijing Municipality, Guangdong Province, and Zhejiang Province of the People’s Republic of China.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating the Allegations that the Board of Global Cord Blood Corporation (CO) Engaged in Self-Serving and Conflicted Transactions

According to the complaint, during the class period, Defendants failed to disclose that: (i) Global Cord employed a capital allocation strategy designed to reserve funds for Company insiders and related parties rather than for the benefit of Company shareholders; (ii) Global Cord’s decisions to reject multiple going private offers and enter into the Transaction were nothing more than self-serving and conflicted attempts by Defendants to divert company funds to corporate insiders and related parties; (iii) Defendants fundamentally misrepresented to investors Global Cord’s approach to capital allocation, strategic investments, acquisitions, and related party transactions as a result of the misappropriation by Defendant Kam and his entities of hundreds of millions of dollars from the Company; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. As a result, the Company's stock has declined, harming investors.

What Now: You may be eligible to participate in the class action against Global Cord Blood Corporation Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by June 24, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Global Cord Blood Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:CO

Release Summary
Robbins LLP is Investigating the Allegations that Rivian Automotive, Inc. (RIVN) Misled Investors Regarding Demand for its Products
Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all investors who purchased or otherwise acquired Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025. Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. For more information, submit a form, email attorney Aaron Dumas...

Investor Notice: Robbins LLP Informs Investors of the Securities Class Action Against Oracle Corporation

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs investors that a class action was filed on behalf of all persons and/or entities who purchased or otherwise acquired Oracle Corporation (NYSE: ORCL) Senior Notes issued pursuant to the Shelf Registration Statement filed with the SEC on March 15, 2024, and as supplemented on September 25, 2025. Oracle is an Austin, Texas-based company that sells database software, enterprise applications, and cloud infrastructure and hardware. For more information,...

Investor Notice: Robbins LLP Informs Investors of the Smart Digital Group Limited Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Smart Digital Group Limited (NASDAQ: SDM) securities between May 5, 2025 and September 26, 2025. Smart Digital, together with its subsidiaries, provides internet media, business planning and consulting, event planning and execution, and software customization and marketing services in Mainland China and Macau. For more information, submit a fo...
Back to Newsroom